The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

##STR00001##

This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold, as shown in Formula (I). ##STR00001##
The phospholidine compounds can include a P-phenyl phospholidine moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phospholidine moiety can be optionally substituted at phosphorus with thio (S) instead of oxo (O). A second heteroatom attached to phosphorus can be cyclically linked to the N-substituted nitrogen atom of the phospholidine that is attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.

The present specification provides a heterocyclic compound and an organic light emitting device using the same.

This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. Acyl phosphonamidate compounds may include a P-phenyl phosphonamidate moiety which is N-acylated with an aroyl or heteroaroyl group. The P-phenyl phosphonamidate moiety can be optionally substituted at phosphorus with thio (S) instead of oxo (O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus can be cyclically linked to a carbon atom of the adjacent phenyl ring attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

In accordance with the disclosure, one aspect of the present application is directed to a lubricant additive composition. The lubricant additive composition includes a component or mixture of components selected from (a) an aminoalkylphosphonic acid dialkyl ester; (b) a cyclized product of an aminoalkylphosphonic acid dialkyl ester; and a mixture of (a) and (b). Preparation and use of the additive composition in a lubricant for antiwear and/or friction reduction are also disclosed.

An acridine derivative including a structure of formula (I) is provided. The acridine derivative can be used as a fluorescent material, in particular, it is included in an organic light-emitting layer as a dark blue thermally-activated delayed fluorescent material, thereby a series of high-performance electrothermally activated delayed fluorescent devices are produced.

Compounds of formula (I) ##STR00001##
wherein: Ak.sub.1 represents an alkyl chain, X represents (CH.sub.2).sub.m, CH(R), N(R), CH.sub.2N(R), N(R)CH.sub.2 or CH.sub.2N(R)CH.sub.2, m and R are as defined in the description, R.sub.1 and R.sub.2 each represent H when X represents (CH.sub.2).sub.m, CH(R), N(R), CH.sub.2N(R) or N(R)CH.sub.2, or together form a bond when X represents CH.sub.2N(R)CH.sub.2, R.sub.3 represents NH.sub.2, Cy-NH.sub.2, Cy-Ak.sub.3-NH.sub.2 or piperidin-4-yl, Cy and Ak.sub.3 are as defined in the description, R.sub.4 and R.sub.5, which may be identical or different, each represent H or F,
their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating conditions requiring a TAFIa inhibitor.

Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3 and/or 5-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.